In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Coronary Artery Disease
About this trial
This is an interventional other trial for Coronary Artery Disease focused on measuring coronary artery disease, platelet function, ticagrelor, cangrelor
Eligibility Criteria
Inclusion criteria:
- Patients with angiographically documented coronary artery disease.
- Age between 18 to 80 years
- On treatment per standard of care with ticagrelor 90mg/b.i.d. and aspirin <100mg/day for at least 14 days.
Exclusion criteria
- History of intracranial bleeding
- Known severe hepatic dysfunction
- Known hypersensitivy
- Active bleeding or propensity to bleed
- Platelet count <80x106/mL
- Hemodynamic instability
- Serum creatinine <30 mL/min
- Use of oral anticoagulants (Vitamin K antagonist, dabigatran, rivaroxaban, apixaban)
- Recent (<14 days) antiplatelet treatment with a glycoprotein IIb/IIIa inhibitor
- Blood dyscrasia
- Patients with sick sinus syndrome (SSS) or II or III degree AV block without pacemaker
- Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromizycin
- Hemoglobin < 10g/dL
- Pregnant females [women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study].
Sites / Locations
- Dominick Angiolillo
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Ticagrelor 180mg
Ticagrelor 90mg
The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.